mitoxantrone liposome + cytarabine

This drug is a **combination regimen** of *mitoxantrone hydrochloride liposome* (a pegylated liposomal formulation of mitoxantrone, an anthracenedione antineoplastic agent) and *cytarabine* (a nucleoside analog used as a chemotherapeutic). The liposomal encapsulation of mitoxantrone is designed to provide enhanced pharmacokinetics, efficacy, and lower toxicity compared to the non-liposomal form. The combination is under investigation primarily for the treatment of **acute myeloid leukemia (AML)**, including newly diagnosed secondary AML (sAML) and relapsed/refractory AML (R/R AML). Mechanistically, mitoxantrone acts as a DNA intercalator and topoisomerase II inhibitor, resulting in DNA strand breaks, while cytarabine is incorporated into DNA, inhibiting DNA polymerase and blocking DNA synthesis. The combination is being evaluated in clinical trials, usually administered by intravenous infusion, and often in regimens combined with other agents such as cyclophosphamide or venetoclax[1][2][3][4][5][6][7][8].

Other names

mitoxantrone hydrochloride liposome + cytarabine